Published in Front Pediatr on April 07, 2015
Bronchiectasis and other chronic lung diseases in adolescents living with HIV. Curr Opin Infect Dis (2016) 0.75
Editorial: Pediatric Pulmonary Hypertension. Front Pediatr (2015) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2013) 8.29
A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med (2011) 7.21
Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med (2001) 6.01
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 5.79
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol (2013) 4.89
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2011) 4.31
Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Primary pulmonary hypertension in HIV infection. Chest (1991) 2.40
Incubation period of AIDS in San Francisco. Nature (1989) 2.26
Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13
Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS (2008) 2.12
Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation (2000) 2.04
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med (2007) 2.03
Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation (2000) 1.97
Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis (2002) 1.94
Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection. Clin Infect Dis (2012) 1.90
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis (2013) 1.90
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis (2004) 1.89
Pediatric pulmonary hypertension. J Am Coll Cardiol (2013) 1.76
Exogenous tat protein activates human endothelial cells. Blood (1993) 1.68
Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation (2011) 1.67
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet (2004) 1.66
Cardiac morbidity and related mortality in children with HIV infection. JAMA (1993) 1.65
High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. Clin Infect Dis (2010) 1.58
HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med (2006) 1.58
Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation (2011) 1.54
Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J (1998) 1.51
Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 1.46
Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly (2001) 1.46
Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol (1997) 1.46
HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest (2000) 1.45
Arteriopathy in macaques infected with simian immunodeficiency virus. Lab Invest (1992) 1.43
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 1.40
HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med (1997) 1.35
HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci U S A (2001) 1.33
Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr (2007) 1.32
Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am Heart J (2005) 1.30
HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS (2010) 1.27
Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol (2000) 1.27
Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc (1998) 1.26
Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation (1994) 1.24
Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis (1992) 1.23
Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS (1999) 1.21
Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun (2005) 1.17
Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med (2000) 1.14
Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS (2008) 1.13
Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia. Am J Pathol (2007) 1.05
Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol (1993) 1.05
Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature. Chest (1992) 1.04
Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr (2006) 1.03
Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol (1987) 1.02
Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect (2000) 1.00
Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart (2006) 0.97
Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med (1996) 0.97
Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension. Am J Respir Cell Mol Biol (2012) 0.97
Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med (2008) 0.96
Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol (2004) 0.96
[Cardiovascular diseases and HIV infection: study of 79 cases at the National Hospital of Ouagadougou (Burkina Faso)]. Bull Soc Pathol Exot (2002) 0.95
Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation (2010) 0.93
The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism. J Biol Chem (2002) 0.93
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther (2005) 0.93
Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. AIDS (2012) 0.92
Role of human immunodeficiency virus in primary pulmonary hypertension--case reports. Angiology (1998) 0.91
Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses (2012) 0.91
AIDS in childhood: cardiac involvement with and without triple combination antiretroviral therapy. Arq Bras Cardiol (2008) 0.89
Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef. Proc Am Thorac Soc (2011) 0.89
Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr (2002) 0.89
Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. AIDS (2014) 0.89
High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses (2012) 0.88
Extracellular HIV-1 Nef increases migration of monocytes. Exp Cell Res (2006) 0.88
Sildenafil in HIV-related pulmonary hypertension. AIDS (2001) 0.88
HIV-related pulmonary hypertension. From pathogenesis to clinical aspects. Acta Cardiol (2004) 0.87
Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med (1994) 0.87
Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS (2005) 0.87
Cardiac manifestations in HIV-infected Thai children. Ann Trop Paediatr (2004) 0.86
Clinical and therapeutical follow-up of HIV-associated pulmonary hypertension: prospective study of 10 patients. AIDS (2003) 0.86
Sildenafil as treatment for Human Immunodeficiency Virus-related pulmonary hypertension in a child. J Paediatr Child Health (2006) 0.85
Human herpesvirus 8 and pulmonary hypertension. Emerg Infect Dis (2005) 0.85
Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS (2002) 0.85
Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol (2013) 0.85
Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am J Med (1990) 0.84
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J (2008) 0.84
Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect (2011) 0.84
Cor pulmonale in children with human immunodeficiency virus infection. Ann Trop Paediatr (1995) 0.84
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J (2004) 0.83
HIV and pulmonary arterial hypertension: a systematic review. HIV Med (2010) 0.83
Current management of primary pulmonary hypertension. Drugs (2001) 0.83
HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS (2008) 0.83
Cardiovascular effects of HAART in infants and children of HIV-infected mothers. Cardiovasc Toxicol (2004) 0.82
Pulmonary hypertension in individuals with HIV infection. AIDS (2006) 0.81
HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors. Biochim Biophys Acta (2007) 0.81
Thrombotic primary pulmonary hypertension in an HIV+ patient. Eur Heart J (1994) 0.79